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ess: paviad@bra.boehriSummary Respimats Soft MistTM Inhaler (SMI) is a new-generation inhaler that
offers improved lung deposition compared with chlorofluorocarbon metered dose
inhalers (CFC-MDIs). Bronchodilators administered via Respimats SMI are preserved
and stabilised with low concentrations of benzalkonium chloride and ethylene
diamine tetra-acetic acid, both of which have been reported to cause dose-related
paradoxical bronchoconstriction. The aim of this analysis was to compare the
incidence of paradoxical bronchoconstriction after chronic use of bronchodilators via
Respimats SMI and CFC-MDI.
Data from three clinical trials, in which patients with asthma or chronic
obstructive pulmonary disease (COPD) received ipratropium bromide alone or in
combination with fenoterol hydrobromide, or placebo via Respimats SMI or CFC-MDI
for 12 weeks, were included in the analysis. In order to evaluate the risk of
paradoxical bronchoconstriction, we identified four respiratory events that might
have occurred within 30min of inhalation on four test days; these were:
‘bronchospasm’, ‘other respiratory adverse events’, ‘rescue medication use’ and
‘asymptomatic drop in FEV1 X15% from baseline’.
In total, 631 asthma and 1538 COPD patients participated in the three studies. No
occurrences of bronchospasm were reported with Respimats SMI on any test day.Elsevier Ltd. All rights reserved.
4 741264; fax: +44 1344 742699.
nger-ingelheim.com (D. Pavia).
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R. Hodder et al.1088Overall, the incidence of respiratory events possibly indicative of paradoxical
bronchoconstriction was low and similar for both devices. There was no increase in
the incidence of events during 12 weeks’ treatment.
Delivery of bronchodilators by Respimats SMI is safe with regard to paradoxical
bronchoconstriction during chronic use in patients with asthma or COPD.
& 2005 Elsevier Ltd. All rights reserved.Mouthpiece
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Figure 1 Schematic diagram of Respimats Soft MistTM
Inhaler.Introduction
Various formulations of b-agonists and other
bronchodilators have been associated with unex-
pected bronchoconstriction in certain individuals,
particularly asthmatic patients1,2; for example,
nebulised solutions of ipratropium bromide and
salbutamol have caused occasional bronchocon-
striction in asthmatic children.3,4 Patients who
report that a bronchodilator makes their respira-
tory symptoms worse should be suspected of having
paradoxical bronchoconstriction. This effect has
also been reported with inhaled steroids.5 Para-
doxical bronchoconstriction is defined as the rapid
onset of unexpected bronchospasm occurring
shortly after the administration of a medicinal
aerosol.
Various mechanisms have been proposed to
explain this phenomenon, including: reactions to
propellants, surfactants or preservatives6,7; airflow
turbulence; the ‘cold freon’ effect; solution osmol-
ality or pH. Benzalkonium chloride (BKC) is in-
cluded in some inhalation formulations to prevent
bacterial growth, especially in multi-dose inhalers
that are opened repeatedly, exposing the medicine
to contamination. Ethylene diamine tetra-acetic
acid (EDTA) may also be included as a preservative
or stabilising agent. Inhalation of these agents
(administered separately) has been reported to
cause dose-related acute decreases in lung function
(forced expiratory volume in one second
[FEV1]).
8–10
Respimats Soft MistTM Inhaler (SMI) (Fig. 1) is a
new generation, propellant-free inhaler that gen-
erates an aerosol cloud with a high fine particle
fraction, allowing a higher proportion of the
emitted dose to be delivered to the lungs than
with other devices, such as the chlorofluorocarbon
metered dose inhaler (CFC-MDI).11 Bronchodilators
administered via Respimats SMI have proven
clinical efficacy and safety in patients with ob-
structive lung disease.12–14 Respimats SMI is a
multi-dose device, necessitating the inclusion of
BKC as an antibacterial agent in the drug solution.
Marketed drug solutions delivered via Respimats
SMI also contain EDTA as a stabilising agent.
The concentrations of BKC and EDTA in aqueous
Respimats SMI formulations are 100 and 500 mg/ml,respectively, and the average actuation volume is
0.011ml. Based on an average lung deposition rate
of 40%,15 the amounts of BKC and EDTA delivered to
the lungs in a single actuation from Respimats SMI
are estimated to be 0.44 and 2.2 mg, respectively
(approximately 200 times lower than that delivered
by wet nebulised solutions). Because the amounts
of BKC and EDTA delivered to the lung from
Respimats SMI are very low, the probability of
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Low incidence of paradoxical bronchoconstriction with Respimats SMI 1089these agents causing bronchoconstriction would
also be expected to be low.
Despite the probable infrequency of Respimats
SMI-induced paradoxical bronchoconstriction, the
serious nature of such reactions makes awareness
of this possibility essential. Koehler et al.16 have
already performed a retrospective analysis of
the incidence of paradoxical bronchoconstriction
in nine phase II (dose-ranging and cumulative
dose–response) studies in patients with asthma or
chronic obstructive pulmonary disease (COPD) who
received single doses of bronchodilator drugs via
Respimats SMI or CFC-MDI. The incidence of
adverse events indicative of paradoxical broncho-
constriction was low (p5%) in those patients using
the Respimats SMI device and similar to that seen
in the CFC-MDI group.
In a follow-up to the retrospective analysis of
single-dose studies (and using the same criteria),
this paper reports the incidence of paradoxical
bronchoconstriction after repeated dosing of
bronchodilators via Respimats SMI or CFC-MDI in
asthma or COPD patients participating in three
phase III studies.1
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.Methods
We analysed three multicentre, randomised, dou-
ble-blind, phase III clinical trials in patients with
either asthma or COPD (these were the only chronic
administration phase III trials completed at the
time of the analysis)12,13,17 (Table 1). Patients
received ipratropium bromide (IB; Atrovents),
ipratropium bromide/fenoterol hydrobromide (IB/
FEN; Beroduals) or placebo one actuation qid via
Respimats SMI or 2 actuations qid from CFC-MDI for
12 weeks (see Table 1 for dosages). The concentra-
tions of BKC and EDTA in the active drug and
placebo formulations were the same in each study.
Pulmonary function tests were performed on the
first day of study treatment and on days 29, 57 and
85. On test days, FEV1 was recorded prior to test
drug administration and at 5, 15, 30 and 60min
post-dose in all three studies. At each timepoint,
pulmonary function tests were performed in tripli-
cate to establish reproducibility.
In order to evaluate the risk of paradoxical
bronchoconstriction, we identified four respiratory
events of interest that might have occurred within
30min after the first dose of trial medication taken
on each test day. These events were as follows:Ta
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r Bronchospasm: Defined as the presence of
spontaneously reported respiratory symptoms
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R. Hodder et al.1090and classified according to World Health Organi-
sation (WHO) preferred terms as ‘bronchospasm’,
‘bronchospasm aggravated’ or ‘bronchospasm
paradoxical’. Any other spontaneously reported WHO respira-
tory system organ class adverse event. Rescue medication use: Defined as the use of
rescue bronchodilator. Asymptomatic drop in FEV1 of X15%: Defined as
a decrease in FEV1 of X15% from baseline.For the purpose of this analysis, respiratory
events that occurred within 30min of inhaling a
treatment on test days were grouped into four
mutually exclusive categories (or combinations)
that suggested the occurrence of paradoxical
bronchoconstriction. These were (in descending
order of how strongly suggestive of paradoxical
bronchoconstriction they were): Category 1: Bronchospasm, with or without any
other event. Category 2: Two or more of, other respiratory
adverse events, rescue medication use or asymp-
tomatic drop in FEV1 of X15% from baseline. Category 3: Either, other respiratory adverse
events or rescue medication use. Category 4: Asymptomatic drop in FEV1 of X15%
only.All events in each category were summed across
the three studies for each treatment arm, distin-
guishing only between active drug and placebo (i.e.
IB and IB/FEN were combined into one ‘active drug’
group).Table 2 Patient demographics and baseline clinical cha
Sex, n (%)
Male
Female
Mean age, years (range)
Mean duration of disease, years (range)
Smoking history, n (%)
Never smoked
Ex-smoker
Smoker
Mean pack years (range)
Mean FEV1, L (SD)
Mean % predicted FEV1 (SD)Statistical analysis
We calculated 95% confidence intervals (CIs) for the
incidence of Category 1 events in asthma and COPD
patients on one or more of the four test days, using
the binomial distribution.Results
A total of 631 patients with asthma (mean age, 41.8
years; mean duration of disease, 19.0 years) and
1538 patients with COPD (mean age, 64.4 years;
mean duration of disease, 9.0 years) participated in
the three studies. For the purposes of this analysis,
the data are presented separately for each disease.
Demographic and baseline clinical characteristics
of all patients are shown in Table 2.
Asthma patients
Active drug and placebo were administered to 313
and 79 patients, respectively, via Respimats SMI
and 159 and 80 patients, respectively, via CFC-MDI.
Of the 631 patients randomised to treatment, 573
inhaled randomised treatment on all four test days.
The number of asthma patients experiencing
respiratory events within 30min of inhaling study
treatment on the four test days is shown in Table 3.
No incidences of Category 1 or Category 2 events
were reported with Respimats SMI on any of the
test days. Only one case of a Category 1 event was
reported with CFC-MDI; this occurred in a patient
receiving placebo on test day 29. Category 3 events
were reported on 5 occasions in patients receiving
treatments via Respimats SMI (active drug, 2;
placebo, 3) and 3 occasions in patients receivingracteristics.
Asthma (n ¼ 631) COPD (n ¼ 1538)
299 (47.4) 1007 (65.5)
332 (52.6) 531 (34.5)
41.8 (17–70) 64.3 (28–90)
19.0 (0.08–65) 9.0 (0.08–50)
356 (56.4) 0 (0.0)
274 (43.4) 881 (57.3)
1 (0.2) 657 (42.7)
2.7 (0–36) 42.4 (8–200)
2.17 (0.63) 1.09 (0.43)
66 (11) 41 (13)
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Table 3 Incidence of respiratory events indicative of paradoxical bronchoconstriction occurring within 30min of inhaling active drug (bronchodilators) or
placebo from Respimats Soft MistTM Inhaler (SMI) or chlorofluorocarbon metered dose inhaler (CFC-MDI) in 631 adult asthma patients on four test days.
Outcome category Treatment Number of patients (%)
Day 1 Day 29 Day 57 Day 85
Category 1 (bronchospasm) Respimats SMI active drug 0 (0) 0 (0) 0 (0) 0 (0)
CFC-MDI active drug 0 (0) 0 (0) 0 (0) 0 (0)
Respimats SMI placebo 0 (0) 0 (0) 0 (0) 0 (0)
CFC-MDI placebo 0 (0) 1 (1.3) 0 (0) 0 (0)
Category 2 (X2 of: other respiratory
events, rescue medication use, or
asymptomatic drop in FEV1)
Respimats SMI active drug 0 (0) 0 (0) 0 (0) 0 (0)
CFC-MDI active drug 0 (0) 0 (0) 0 (0) 0 (0)
Respimats SMI placebo 0 (0) 0 (0) 0 (0) 0 (0)
CFC-MDI placebo 0 (0) 0 (0) 0 (0) 0 (0)
Category 3 (other respiratory events or
rescue medication use)
Respimats SMI active drug 0 (0) 1 (0.3) 1 (0.4) 0 (0)
CFC-MDI active drug 0 (0) 1 (0.6) 0 (0) 0 (0)
Respimats SMI placebo 1 (1.3) 1 (1.3) 0 (0) 1 (1.3)
CFC-MDI placebo 1 (1.3) 0 (0) 0 (0) 1 (1.3)
Category 4 (asymptomatic drop in FEV1) Respimat
s SMI active drug 3 (1.0) 1 (0.3) 3 (1.1) 0 (0)
CFC-MDI active drug 0 (0) 1 (0.6) 0 (0) 0 (0)
Respimats SMI placebo 3 (3.8) 1 (1.3) 1 (1.3) 1 (1.3)
CFC-MDI placebo 6 (7.5) 0 (0) 3 (4.0) 3 (4.0)
No respiratory events Respimats SMI active drug 310 (99.0) 292 (99.3) 281 (98.6) 278 (100.0)
CFC-MDI active drug 159 (100.0) 152 (98.7) 148 (100.0) 147 (100.0)
Respimats SMI placebo 75 (94.9) 74 (97.4) 74 (98.7) 74 (97.4)
CFC-MDI placebo 73 (91.3) 75 (98.7) 72 (96.0) 71 (94.7)
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R. Hodder et al.1092treatments via CFC-MDI (active drug, 1; placebo,
2). The most common event in both the Respimats
SMI and the CFC-MDI groups was an asymptomatic
drop in FEV1 of X15% without any other events
(Category 4), with an incidence on any one test day
of no more than 7.5% in each treatment group.
There was no evidence of an increase in the
incidence of respiratory events during the 12
weeks’ treatment. For both active drug and
placebo, the incidence of all respiratory events
was low and similar for Respimats SMI and CFC-
MDI, although events were slightly more frequent in
the placebo groups for both devices than the active
drug groups.
COPD patients
Active drug and placebo were administered to 798
and 172 patients, respectively, via Respimats SMI
and 392 and 176 patients, respectively, via CFC-
MDI. Of the 1538 patients randomised to treatment,
1303 inhaled randomised treatment on all four test
days.
Table 4 shows the number of COPD patients
experiencing respiratory events within 30min of
inhaling study treatment on all test days. No cases
of Category 1 events were reported with Respi-
mats SMI or CFC-MDI on any of the test days.
Category 2 events were reported on 9 occasions by
patients receiving treatments via Respimats SMI
(active drug, 6; placebo, 3); one incidence of a
Category 2 event was reported with CFC-MDI
(placebo). As for the less serious categories of
events that were deemed to be indicative of
paradoxical bronchoconstriction, the incidences
of Categories 3 and 4 events in each treatment
group (on any one test day) was no more than 0.8%
and 7.6%, respectively.
There was no evidence of an increase in the
incidence of respiratory events during the 12
weeks’ treatment. For both active drug and
placebo, the incidence of respiratory events was
low and similar for Respimats SMI and CFC-MDI. As
seen in the asthma patients, respiratory events
were slightly more frequent in the placebo groups
for both devices.Discussion
This retrospective analysis demonstrated the safety
of the Respimats SMI formulation with regard to
paradoxical bronchoconstriction in patients with
asthma and COPD during chronic use. No cases of
bronchospasm (Category 1 events) were reportedwith Respimats SMI in either asthma or COPD
patients on any of the test days. In addition, the
incidence of other respiratory events deemed to be
indicative of paradoxical bronchoconstriction in
both the Respimats SMI and the CFC-MDI groups
was low for both diseases. These findings agree
with those from the retrospective analysis of nine
single-dose studies mentioned previously, where
the incidence of adverse events indicative of
paradoxical bronchoconstriction was low in those
patients using Respimats SMI and similar to that
seen in the CFC-MDI group.16
Given that no Category 1 events occurred in any
of the 1362 patients who used Respimats SMI, we
calculated the 95% CI for the incidence of these
events in both asthma and COPD patients. The 95%
CI for the percentage of Category 1 events in the
asthma population was 0–0.8%, indicating that the
true incidence of these events is almost certainly
o0.8%. The 95% CI for the percentage of Category 1
events in the COPD population was 0–0.3%, indicat-
ing that the true incidence of these events in this
population is almost certainly o0.3%.
The incidence of all respiratory events was
similar throughout the 12-week trial period for
both asthma and COPD patients. This indicates that
repeated exposure to BKC and EDTA via Respimats
SMI did not increase the likelihood of experiencing
paradoxical bronchoconstriction. It has been re-
ported that the lowest dose of BKC required to
produce a 20% decrease in FEV1 in asthmatic
patients is in excess of 100 mg.9 As stated earlier,
the amount of BKC delivered to the lungs in a single
actuation from Respimats SMI is estimated to be
0.44 mg; thus, repeated exposure to such a small
dose via Respimats SMI is unlikely to cause
paradoxical bronchoconstriction. EDTA is a much
less potent bronchoconstrictor than BKC; indeed,
the amount of EDTA contained in the maximum
recommended doses of nebulised bronchodilators
(up to 600 mg) has not been shown to induce
bronchospasm in asthmatic patients following
repeated use.18 As the amount of EDTA delivered
via Respimats SMI is extremely low (approximately
2.2 mg/actuation), it is not surprising that in our
analysis we observed a very low incidence of events
indicative of paradoxical bronchoconstriction.
Estimation of the incidence of paradoxical
bronchoconstriction in patients who regularly use
CFC-MDIs was first provided in a prospective study
by Yarbrough et al.19 The investigators reported
that 23 of 1450 asthma patients (1.6%) experienced
immediate bronchoconstriction (defined as aX10%
decrease in FEV1 within 10min of inhalation) after
using salbutamol via CFC-MDI. In a second study,
the same investigators observed a decrease of
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Table 4 Incidence of respiratory events indicative of paradoxical bronchoconstriction occurring within 30min of inhaling active drug (bronchodilators) or
placebo from Respimats Soft MistTM Inhaler (SMI) or chlorofluorocarbon metered dose inhaler (CFC-MDI) in 1538 COPD patients on four test days.
Outcome category Treatment Number of patients (%)
Day 1 Day 29 Day 57 Day 85
Category 1 (bronchospasm) Respimats SMI active drug 0 (0) 0 (0) 0 (0) 0 (0)
CFC-MDI active drug 0 (0) 0 (0) 0 (0) 0 (0)
Respimats SMI placebo 0 (0) 0 (0) 0 (0) 0 (0)
CFC-MDI placebo 0 (0) 0 (0) 0 (0) 0 (0)
Category 2 (X2 of: other respiratory
events, rescue medication use, or
asymptomatic drop in FEV1)
Respimats SMI active drug 2 (0.3) 1 (0.1) 3 (0.4) 0 (0)
CFC-MDI active drug 0 (0) 0 (0) 0 (0) 0 (0)
Respimats SMI placebo 0 (0) 1 (0.6) 1 (0.7) 1 (0.7)
CFC-MDI placebo 1 (0.6) 0 (0) 0 (0) 0 (0)
Category 3 (other respiratory events or
rescue medication use)
Respimats SMI active drug 1 (0.1) 2 (0.3) 1 (0.1) 2 (0.3)
CFC-MDI active drug 1 (0.3) 3 (0.8) 1 (0.3) 2 (0.6)
Respimats SMI placebo 1 (0.6) 1 (0.6) 1 (0.7) 1 (0.7)
CFC-MDI placebo 1 (0.6) 1 (0.6) 0 (0) 0 (0)
Category 4 (asymptomatic drop in FEV1) Respimat
s SMI active drug 22 (2.8) 14 (1.9) 7 (1.0) 16 (2.3)
CFC-MDI active drug 7 (1.8) 3 (0.8) 5 (1.5) 3 (0.9)
Respimats SMI placebo 13 (7.6) 11 (7.1) 4 (2.8) 7 (4.9)
CFC-MDI placebo 9 (5.1) 5 (3.1) 7 (4.6) 3 (2.1)
No respiratory events Respimats SMI active drug 773 (96.9) 723 (97.7) 691 (98.4) 670 (97.4)
CFC-MDI active drug 384 (98.0) 360 (98.4) 336 (98.2) 329 (98.5)
Respimats SMI placebo 158 (91.9) 142 (91.6) 138 (95.8) 133 (93.7)
CFC-MDI placebo 165 (93.8) 153 (96.2) 145 (95.4) 143 (97.9)
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R. Hodder et al.1094X15% in FEV1 in 25 of 900 asthma patients (2.8%)
who received orciprenaline via CFC-MDI and 10 of
175 asthma patients (5.7%) who received placebo
via CFC-MDI.20 The placebo group results in this
second study suggested that when the bronchodi-
lator drug is removed, the incidence of events
possibly indicative of paradoxical bronchoconstric-
tion is greater. This effect was seen in our study, in
which respiratory events were slightly more fre-
quent in the placebo groups for both devices; the
incidence of asymptomatic falls in FEV1 of X15%:
from baseline (Category 4 events) was 0.0–2.8% in
the active treatment groups compared with
0.0–7.6% in the placebo groups. Huchon et al.21
compared the incidence of adverse events, with
particular attention given to bronchospasm, in 2027
patients with chronic airways obstruction following
12 weeks’ treatment with IB/FEN delivered via a
CFC-MDI and a hydrofluoroalkane- (HFA)-MDI.21
Bronchospasm was defined as an adverse event if
it was reported by the patient, or if there was a
415% fall in FEV1 from baseline within 15min
following inhalation of test drug. No difference
between formulations was observed in the inci-
dence of bronchospasm; the incidence of falls in
FEV1 415% within 15min following inhalation was
1.2% for both CFC- and HFA-MDIs. Shaheen et al.
studied the incidence of acute decreases in peak
expiratory flow (PEF) following the use of MDIs in
11 850 patients with asthma.22 Two different
placebo-containing MDI preparations were com-
pared with a MDI containing salmeterol. A fall of
X20% in PEF was defined as a clinically significant
bronchoconstriction. A significantly lower inci-
dence of bronchoconstriction was observed with
the salmeterol-containing MDI compared with
either of the placebo preparations (1.1% versus
1.7% and 1.8%, respectively).
Some studies have shown no difference in the
incidence of paradoxical bronchoconstriction fol-
lowing inhalation of preservative-containing and
preservative-free solutions of bronchodilators.
Henry et al.23 found no significant difference in
the extent of bronchodilation following inhalation
of a solution of IB that contained BKC and EDTA and
a solution that was preservative-free. Similarly,
Kwong et al. showed that the presence of BKC
(0.1mg/ml) did not affect the short-term airways
response to a single dose of inhaled salbutamol
nebuliser solution in patients with mild asthma.24
Australian investigators examined the acute effects
of IB in patients with asthma using formulations
with and without preservatives.25 Twenty-five
patients with stable asthma and 25 patients with
acute asthma were studied. Preservative-contain-
ing IB did not cause a fall in FEV1 in any of thepatients with stable asthma, and in only one of the
patients with acute asthma. In both patient groups,
no fall in FEV1 occurred when preservative-free IB
was used.
In the three clinical trials included in this
analysis, pulmonary function tests were performed
in triplicate to establish reproducibility. Some
studies have suggested that repeated spirometry
efforts may act as a trigger for bronchoconstriction,
as evidenced by a fall in FEV1 with successive
attempts.26–28 Consequently, the incidence of
Category 4 events reported in this analysis may
not reflect administration-induced paradoxical
bronchoconstriction alone, but may in part be due
to repeated spirometric manoeuvres. In our analy-
sis, it is worth noting that the incidence of events
deemed to be indicative of paradoxical broncho-
constriction was higher in the COPD population
than the asthma population. We would have
expected the incidence to be higher in the more
hyper-reactive asthma population.
In conclusion, our analysis confirms that admin-
istering bronchodilators via Respimats SMI is safe
with regard to paradoxical bronchoconstriction
during chronic use in patients with asthma or COPD.References
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